The consequences of doxorubicin quinone reduction in vivo in tumour tissue.
Affiliation
Imperial Cancer Research Fund, Western General Hospital, Edinburgh, U.K.Issue Date
1992-12-01
Metadata
Show full item recordAbstract
A clear role for quinone reduction in the mechanism of action of doxorubicin has still to be established. There are three possible outcomes of this form of doxorubicin metabolism: (1) drug free radical formation, redox cycling and generation of reactive oxygen species (ROS) resulting in lipid peroxidation and DNA damage; (2) covalent binding of reactive drug intermediates to DNA; and (3) formation of an inactive 7-deoxyaglycone metabolite. In this work, the occurrence of each of these pathways has been studied in vivo in a subcutaneously growing rat mammary carcinoma (Sp 107). Doxorubicin was administered by direct intratumoural injection either as the free drug or incorporated in albumin microspheres (10-40 microns diameter). There was no evidence of an increase in lipid peroxidation over background after either treatment at any time point studied. In fact, doxorubicin administration resulted in a statistically significant reduction in lipid peroxidation at the later time points studied compared to control (no drug treatment), e.g. 24 hr: control, 21.7 +/- 2.8 SD nmol malondialdehyde/g tissue; free doxorubicin (70 micrograms drug), 14.5 +/- 4.0 SD nmol/g (P < 0.01 Student's t-test) and doxorubicin microspheres (70 micrograms drug), 17.4 +/- 1.1 nmol/g (P < 0.05). Covalent binding to DNA was measured by a 32P-post-labelling technique. Low levels of four putative drug-DNA adducts were detected; however, there were no qualitative or quantitative differences in profiles between free drug and microspheres. High 7-deoxyaglycone metabolite concentrations comparable to the parent drug itself were detected after administration of microspheres (3.0 micrograms/g +/- 1.7 SD at 24 hr and 3.1 micrograms/g +/- 1.1 SD at 48 hr). In contrast, these metabolites were present at levels close to the limit of detection of our HPLC assay after free drug (0.04 microgram/g +/- 0.03 SD at 24 hr and 0.02 microgram/g +/- 0.03 SD at 48 hr). Thus, 7-deoxyaglycone metabolite formation can occur in tumour tissue (indicating active drug quinone reduction) without concomitant increases in the level of lipid peroxidation or the levels of drug-DNA adducts. In conclusion, the main biological consequence of doxorubicin quinone reduction in vivo in tumour tissue would appear to be drug inactivation to a 7-deoxyaglycone metabolite rather than drug activation to DNA reactive species or ROS.Citation
The consequences of doxorubicin quinone reduction in vivo in tumour tissue. 1992, 44 (11):2165-74 Biochem. Pharmacol.Journal
Biochemical PharmacologyDOI
10.1016/0006-2952(92)90343-HPubMed ID
1472081Type
ArticleLanguage
enISSN
0006-2952ae974a485f413a2113503eed53cd6c53
10.1016/0006-2952(92)90343-H
Scopus Count
Collections
Related articles
- The enzymology of doxorubicin quinone reduction in tumour tissue.
- Authors: Cummings J, Allan L, Willmott N, Riley R, Workman P, Smyth JF
- Issue date: 1992 Dec 1
- Relationship between reductive drug metabolism in tumour tissue of anthracyclines in microspherical form and anti-tumour activity.
- Authors: Willmott N, Cummings J, Marley E, Smyth JF
- Issue date: 1990 Mar 15
- Covalent coupling of doxorubicin in protein microspheres is a major determinant of tumour drug disposition.
- Authors: Cummings J, Willmott N, Marley E, Smyth J
- Issue date: 1991 Jun 15
- Encapsulation of mitomycin C in albumin microspheres markedly alters pharmacokinetics, drug quinone reduction in tumour tissue and antitumour activity. Implications for the drugs' in vivo mechanism of action.
- Authors: Cummings J, Allan L, Smyth JF
- Issue date: 1994 Apr 20
- Increased anti-tumor effect of adriamycin-loaded albumin microspheres is associated with anaerobic bioreduction of drug in tumor tissue.
- Authors: Willmott N, Cummings J
- Issue date: 1987 Feb 15